Stayble Therapeutics AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2016 - 2019
Net Income	-	-23.74	-24.53	-12.09	-15.49	Upgrade
Other Operating Activities	-	0.19	-0.26	-0.08	0.17	Upgrade
Change in Accounts Receivable	-	-1.32	-0.13	0.96	-1.23	Upgrade
Change in Other Net Operating Assets	-	1.33	0.03	1.58	-7.43	Upgrade
Operating Cash Flow	-	-23.54	-24.89	-9.63	-23.98	Upgrade
Investment in Securities	-	-	-	-0	-	Upgrade
Investing Cash Flow	-	-	-	-0	-	Upgrade
Long-Term Debt Issued	-	-	0	-	-	Upgrade
Long-Term Debt Repaid	-	-	-	-0.19	-0.14	Upgrade
Net Debt Issued (Repaid)	-	-	0	-0.19	-0.14	Upgrade
Issuance of Common Stock	-	31.82	-	41.54	35.14	Upgrade
Other Financing Activities	-	-6.85	-	-5.19	-3.81	Upgrade
Financing Cash Flow	-	24.96	0	36.15	31.19	Upgrade
Foreign Exchange Rate Adjustments	-	-0.19	0.26	0.08	-0.17	Upgrade
Net Cash Flow	-	1.23	-24.62	26.6	7.04	Upgrade
Levered Free Cash Flow	-	-15.08	-15.71	-5.09	-18.11	Upgrade
Unlevered Free Cash Flow	-	-15.06	-15.69	-5.05	-17.86	Upgrade
Change in Working Capital	-	0.01	-0.1	2.54	-8.66	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.